WO2007054269A2 - Extrakte aus der rinde von corynanthe-arten und deren verwendung sowie diese extrakte enthaltende arzneimittel, diätetische lebensmittel und pharmazeutische zubereitungen - Google Patents
Extrakte aus der rinde von corynanthe-arten und deren verwendung sowie diese extrakte enthaltende arzneimittel, diätetische lebensmittel und pharmazeutische zubereitungen Download PDFInfo
- Publication number
- WO2007054269A2 WO2007054269A2 PCT/EP2006/010663 EP2006010663W WO2007054269A2 WO 2007054269 A2 WO2007054269 A2 WO 2007054269A2 EP 2006010663 W EP2006010663 W EP 2006010663W WO 2007054269 A2 WO2007054269 A2 WO 2007054269A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extract
- disorders
- extracts
- corynanthe
- bark
- Prior art date
Links
- MOJZMWJRUKIQGL-XILRTYJMSA-N O[C@H](C1)[C@@H](c(cc2O)ccc2O)Oc2c1c(O)cc(O)c2[C@H]([C@H]([C@@H](c(cc1O)ccc1O)Oc1c([C@H]([C@H]([C@@H](c(cc2)cc(O)c2O)Oc2cc(O)c3)O)c2c3O)c(O)c2)O)c1c2O Chemical compound O[C@H](C1)[C@@H](c(cc2O)ccc2O)Oc2c1c(O)cc(O)c2[C@H]([C@H]([C@@H](c(cc1O)ccc1O)Oc1c([C@H]([C@H]([C@@H](c(cc2)cc(O)c2O)Oc2cc(O)c3)O)c2c3O)c(O)c2)O)c1c2O MOJZMWJRUKIQGL-XILRTYJMSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- alpha-blockers include dizziness, headache, weakness, orthostatic dysregulation, rhinitis and sexual dysfunction (retrograde ejaculation), which are mainly due to the effects on alpha receptors in the CNS and cardiovascular system.
- subtype-specific alpha-blockers that primarily inhibit ⁇ -1 A and ⁇ -1 D receptors (eg, tamsulosin)
- tamsulosin a subtype-specific alpha-blockers that primarily inhibit ⁇ -1 A and ⁇ -1 D receptors
- the non-selective ⁇ r-antagonist alfuzosin has a similarly favorable side-effect profile as tamsulosin, which is commonly described as a uroselective ⁇ -i blocker.
- Corynanthe pachyceras is an approximately 15 - 2O m tall tree with a trunk diameter up to 60 cm, which grows in the evergreen tropical rain forest in West Africa (Sierra Leone to Zaire).
- the wood is mainly used for building, but also for the production of mortars and combs.
- the dried stem bark finds broad folk medicine application. For colds, it is chewed and used as a decoction for leprosy, stomach problems, diarrhea or heart and kidney problems. In the form of teas, the bark is used as an antipyretic agent in malaria, as well as an aphrodisiac and wax preservative.
- Corynanthe pachyceras is used as a preferred Corynanthe species.
- the extracts of the bark of Corynanthe species according to the invention contain both polyphenols and alkaloids, in a balanced ratio for the intended use.
- the contents of polyphenols are preferably at least 15%, particularly preferably at least 24%, and at alkaloids at least 8%, particularly preferably at least 12%.
- typical polyphenols we have isolated the compounds epicatechin, procyanidin B2 and procyanidin C1 from Corynanthe pachyceras.
- the Corynanthe polyphenols are not limited to these three compounds.
- the extracts and extract fractions according to the invention can preferably be administered orally in the form of drops, powders, granules, tablets, dragées or capsules.
- parenteral administration in the form of a solution for injection or topical application in the form of creams, ointments, suppositories, patches or similar preparations is also possible.
- NIH-3T3 mouse fibroblasts The cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS), 2 mM glutamine and antibiotic / antimycotic solution. The change of the culture medium took place regularly twice a week. Four days after the last subculture, the adherent cells were detached with trypsin / EDTA from the bottom of the cell culture flask and resuspended at a density of 50,000 cells per ml in DMEM supplemented with 0.5% FCS.
- DMEM Dulbecco's modified Eagle's medium
- FCS fetal calf serum
- FCS fetal calf serum
- mice Male NMRI mice (Janvier, Le Genest, France) with Triton WR1339-induced hypercholesterolemia.
- the mice were kept under standardized environmental conditions (21 ° C, 60% relative humidity, 12 / 12h light / dark) and had free access to drinking water and pelleted feed (Altromin 1324).
- Triton-WR1339 400 mg / kg, Sigma was dissolved in physiological NaCl solution and injected into the animals via the tail vein (10 ml / kg).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Gynecology & Obstetrics (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/084,745 US20090142428A1 (en) | 2005-11-08 | 2006-11-07 | Extracts from the Bark of Corynanthe Species and Use Thereof as Well as Medicaments, Dietetic Food Products and Pharmaceutical Preparations Containing Said Extracts |
JP2008539325A JP5435951B2 (ja) | 2005-11-08 | 2006-11-07 | コリナンテ種の樹皮からの抽出物、その使用、およびそれを含有する薬剤、ダイエット食品および医薬品 |
AU2006312678A AU2006312678B2 (en) | 2005-11-08 | 2006-11-07 | Extracts from the bark of corynanthe species, use thereof, and medicaments, dietary products, and pharmaceutical preparations containing said extracts |
CA002624703A CA2624703A1 (en) | 2005-11-08 | 2006-11-07 | Extracts from the bark of corynanthe species and use thereof as well as medicaments, dietetic food products and pharmaceutical preparations containing said extracts |
EP06818406A EP1945238A2 (de) | 2005-11-08 | 2006-11-07 | Extrakte aus der rinde von corynanthe-arten und deren verwendung sowie diese extrakte enthaltende arzneimittel, diätetische lebensmittel und pharmazeutische zubereitungen |
BRPI0618634-3A BRPI0618634A2 (pt) | 2005-11-08 | 2006-11-07 | extrato a partir do córtice da espécie da corynanthe pachyceras, uso dos mesmos, medicamento ou produto alimentìcio bem como preparação farmacêutica compreendendo o dito extrato |
KR1020087013748A KR101306599B1 (ko) | 2005-11-08 | 2006-11-07 | 코리난테 종의 수피로부터의 추출물 및 이의 용도, 및 상기추출물을 포함하는 약제, 식이요법 식품 및 약제학적 제제 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102005053241A DE102005053241A1 (de) | 2005-11-08 | 2005-11-08 | Extrakte aus der Rinde von Corynanthe-Arten und deren Verwendung sowie diese Extrakte enthaltende Arzneimittel, diätetische Lebensmittel und pharmazeutische Zubereitungen |
DE102005053241.1 | 2005-11-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007054269A2 true WO2007054269A2 (de) | 2007-05-18 |
WO2007054269A3 WO2007054269A3 (de) | 2007-08-09 |
Family
ID=37982546
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2006/010663 WO2007054269A2 (de) | 2005-11-08 | 2006-11-07 | Extrakte aus der rinde von corynanthe-arten und deren verwendung sowie diese extrakte enthaltende arzneimittel, diätetische lebensmittel und pharmazeutische zubereitungen |
Country Status (12)
Country | Link |
---|---|
US (1) | US20090142428A1 (de) |
EP (1) | EP1945238A2 (de) |
JP (1) | JP5435951B2 (de) |
KR (1) | KR101306599B1 (de) |
CN (1) | CN101291682A (de) |
AU (1) | AU2006312678B2 (de) |
BR (1) | BRPI0618634A2 (de) |
CA (1) | CA2624703A1 (de) |
DE (1) | DE102005053241A1 (de) |
RU (1) | RU2399378C2 (de) |
UA (1) | UA94434C2 (de) |
WO (1) | WO2007054269A2 (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101683337B (zh) * | 2008-09-27 | 2011-12-07 | 复旦大学 | 柯楠因在制备治疗心肌损伤性心脏病药物中的用途 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011125331A (ja) * | 2009-11-17 | 2011-06-30 | Taisho Pharmaceutical Co Ltd | 魚鱗粉末含有コーティング錠剤 |
CN102002039B (zh) * | 2010-11-12 | 2012-05-09 | 天医堂(厦门)生物工程有限公司 | 一种从育亨宾树皮中提取育亨宾的方法 |
CN102030747A (zh) * | 2010-11-19 | 2011-04-27 | 陕西嘉禾植物化工有限责任公司 | 一种育亨宾碱的制备方法 |
EP3646871A1 (de) * | 2018-10-30 | 2020-05-06 | SEROJAC PME Handels GmbH | Behandlung und prävention von vorzeitiger ejakulation |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE758049A (en) * | 1970-10-27 | 1971-04-01 | Omnium Chimique Sa | Hypotensive, sedative extract of pseudocni - chona africana |
FR2112344A1 (en) * | 1970-10-27 | 1972-06-16 | Omnium Chimique Sa | Hypotensive, sedative extract of pseudocni - chona africana |
DE3204960A1 (de) * | 1982-02-12 | 1983-08-25 | Fa. Dr. Willmar Schwabe, 7500 Karlsruhe | Corynanthein-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
US6323211B1 (en) * | 1996-02-02 | 2001-11-27 | Nitromed, Inc. | Compositions and methods for treating sexual dysfunctions |
FR2765483B1 (fr) * | 1997-07-04 | 2000-02-04 | Philippe Gorny | Medicament destine a traiter les dysfonctions erectiles |
IT1293539B1 (it) * | 1997-07-16 | 1999-03-01 | Sigma Tau Ind Farmaceuti | Composizione nutritiva per soggetti in stato di debilitazione causato da stress |
ITMI20011237A1 (it) * | 2001-06-12 | 2002-12-12 | Enzo Leone | Uso della yohimbina per la preparazione di farmaci ad attivita' immunobiologica |
-
2005
- 2005-11-08 DE DE102005053241A patent/DE102005053241A1/de not_active Withdrawn
-
2006
- 2006-11-07 UA UAA200807765A patent/UA94434C2/ru unknown
- 2006-11-07 WO PCT/EP2006/010663 patent/WO2007054269A2/de active Application Filing
- 2006-11-07 EP EP06818406A patent/EP1945238A2/de not_active Withdrawn
- 2006-11-07 RU RU2008119965/21A patent/RU2399378C2/ru not_active IP Right Cessation
- 2006-11-07 BR BRPI0618634-3A patent/BRPI0618634A2/pt not_active IP Right Cessation
- 2006-11-07 CA CA002624703A patent/CA2624703A1/en not_active Abandoned
- 2006-11-07 CN CNA2006800388275A patent/CN101291682A/zh active Pending
- 2006-11-07 KR KR1020087013748A patent/KR101306599B1/ko not_active IP Right Cessation
- 2006-11-07 US US12/084,745 patent/US20090142428A1/en not_active Abandoned
- 2006-11-07 AU AU2006312678A patent/AU2006312678B2/en not_active Ceased
- 2006-11-07 JP JP2008539325A patent/JP5435951B2/ja not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
None |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101683337B (zh) * | 2008-09-27 | 2011-12-07 | 复旦大学 | 柯楠因在制备治疗心肌损伤性心脏病药物中的用途 |
Also Published As
Publication number | Publication date |
---|---|
JP5435951B2 (ja) | 2014-03-05 |
JP2009514916A (ja) | 2009-04-09 |
UA94434C2 (ru) | 2011-05-10 |
RU2399378C2 (ru) | 2010-09-20 |
CN101291682A (zh) | 2008-10-22 |
KR20080071172A (ko) | 2008-08-01 |
BRPI0618634A2 (pt) | 2011-09-06 |
DE102005053241A1 (de) | 2007-05-16 |
KR101306599B1 (ko) | 2013-09-10 |
AU2006312678B2 (en) | 2013-03-28 |
AU2006312678A1 (en) | 2007-05-18 |
CA2624703A1 (en) | 2007-05-18 |
US20090142428A1 (en) | 2009-06-04 |
WO2007054269A3 (de) | 2007-08-09 |
RU2008119965A (ru) | 2009-12-20 |
EP1945238A2 (de) | 2008-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wahida et al. | Antiulcerogenic activity of Zizyphus lotus (L.) extracts | |
DE69837551T2 (de) | Zusammensetzung und verfahren zur behandlung der alzheimer'schen krankheit und anderen amyloidosen | |
EP1171141B1 (de) | ARZNEIMITTEL ZUR HEMMUNG DES NF-kB TRANSKRIPTIONSFAKTORS | |
WO2007054269A2 (de) | Extrakte aus der rinde von corynanthe-arten und deren verwendung sowie diese extrakte enthaltende arzneimittel, diätetische lebensmittel und pharmazeutische zubereitungen | |
WO2002000236A1 (de) | Extrakte aus sophora-arten, verfahren zu ihrer herstellung und verwendung | |
Toklo et al. | Phytochemistry and pharmacological review of Mitragyna inermis (Willd.) Kuntze (Rubiaceae) | |
Rashid et al. | In vivo investigation of the inhibitory effect of Peganum harmala L. and its major alkaloids on ethylene glycol-induced urolithiasis in rats | |
CN1304314A (zh) | 贯叶金丝桃提取物及其制剂 | |
Rattmann et al. | Nitric oxide-dependent vasorelaxation induced by extractive solutions and fractions of Maytenus ilicifolia Mart ex Reissek (Celastraceae) leaves | |
Reddy et al. | Anti-diabetic activity of ethanolic extract of Hydnocarpus wightiana Blume using STZ induced diabetes in SD rats | |
Shiny et al. | Phytochemical and hypoglycaemic activity investigation of Costus pictus plants from Kerala and Tamilnadu | |
Mehesare et al. | Evaluation of antidiarrhoeal activity of polyherbal preparation | |
US11173142B2 (en) | Cancer treatment composition | |
Basa’ar et al. | Screening of supercritical fluid extract of Gymnema sylvestre R. Br. roots for phytochemical and pharmacological analysis | |
Akter et al. | In vitro antioxidant and in vivo antidiarrhoeal activity of hydromethanolic extract of Xanthium indicum Koenig. leaves | |
Sahay et al. | Antioxidant activity of tectona grandis linn stem bark extract | |
Hasan et al. | Antinociceptive and CNS depressant activities of Xanthium indicum Koen. in mice | |
Banpure12 et al. | Anti-Alzhimer Activity of Bay Leaves in Scopolamine-induced Rat Model | |
Gupta et al. | Screening of Anti-Hyperglycaemic and Anti-Hyperlipidemic Activities of Leaves Extracts of Cassia glauca Lam. on Streptozotocin-Nicotinamide Induced NIDDM Rats | |
Al-mously et al. | The Effect of Capparis spinosa Extract on Induced PCOS Mice | |
Rufa’i et al. | EFFECT of METHANOL and ACETONIC EXTRACTS of Bombax ceiba LEAVES on ALLOXAN INDUCED DIABETIC RATS | |
Rahman et al. | Qualitative phytochemical screening and evaluation of analgesic and antidiarrheal activity of ethanolic extract of Leucas cephalotes leaves | |
Deepika et al. | Evaluation of Anti-nephrotoxic potential of leaf extracts of Tamilnadiaulginosa against Gentamicin-induced Nephrotoxicity | |
Tchogou | Toxicity Assessment of Sarcocephalus latifolius Root Extract | |
MX2008005921A (en) | Extracts from the bark of corynanthe species, use thereof, and medicaments, dietary products, and pharmaceutical preparations containing said extracts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680038827.5 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2624703 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006312678 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2008539325 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2008/005921 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12084745 Country of ref document: US |
|
REEP | Request for entry into the european phase |
Ref document number: 2006818406 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006818406 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006312678 Country of ref document: AU Date of ref document: 20061107 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006312678 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087013748 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008119965 Country of ref document: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 2006818406 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0618634 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080508 |